Clinical Trial Update: An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating daratumumab in adults with multiple myeloma who had at least 3 prior therapies or were refractory to a PI and IMiD; the stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Daratumumab (daratumumab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2017-02-02